Cat. No. 3967
Chemical Name: 2-Chloro-N-[1-[(2R)-2,3-dihydroxypr
Biological ActivityAllosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239. PMID: 17934512.
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775. PMID: 17016495.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GPi 688 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GPi 688, supplier, GPi688, glycogen, phosphorylase, inhibitors, hyperglycaemia, hyperglycemia, inhibits, astrazeneca, Tocris Bioscience, Phosphorylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent cholesteryl ester transfer protein (CETP) inhibitorPerhexiline maleate
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.